PDF DatasheetHuman Anti-Luteinizing Hormone / LHCGR Antibody Product Attributes
Species: Human
Tested Applications: Immunohistochemistry (IHC).
Clonality: Monoclonal
Anti-Luteinizing Hormone / LHCGR Antibody Clone: LHCGR/1417
Clone LHCGR/1417 Host and Isotype: Mouse IgG1 kappa
Anti-Human Luteinizing Hormone / LHCGR Positive Control Sample: HepG2 or Jurkat cells. Ovarian Carcinoma
Cellular Localization of Antibody Cytoplasmic and Cell Surface
Buffer and Stabilizer: 10mM PBS with 0.05% BSA and 0.05% Azide
Antibody Concentration: 200 ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Recombinant N-terminal fragment of human LHCGR
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
Luteinizing Hormone / LHCGR Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Luteinizing Hormone / LHCGR expression as measured by anti-Luteinizing Hormone / LHCGR antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | ++ | – | – | + | – | – | + | + | – | + | – | – | + | ++ | + | – | + | ++ | + |
| LHCGR Variability | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | ++ | ++ | + | +++ | ++ | ++ |
| Luteinizing Hormone / LHCGR General Information | |
|---|---|
| Alternate Names | |
| The luteinizing hormone / choriogonadotropin receptor, LHCGR, lutropin / choriogonadotropin receptor, LCGR, luteinizing hormone receptor, LHR, | |
| Molecular Weight | |
| 78-85kDa | |
| Chromosomal Location | |
| 2p21 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | LHCGR |
| Entrez Gene ID | 3973 |
| Ensemble Gene ID | ENSG00000138039 |
| RefSeq Protein Accession(s) | XP_006712078, XP_011531133, XP_016859579, XP_005264366, XP_011531136, XP_016859578, XP_011531130, NP_000224 |
| RefSeq mRNA Accession(s) | XM_011532828, XM_011532831, XM_017004090, XM_011532834, XM_006712015, XM_017004089, NM_000233 |
| RefSeq Genomic Accession(s) | NG_008193, NG_033050, NC_000002, NC_018913 |
| UniProt ID(s) | P22888 |
| UniGene ID(s) | P22888 |
| HGNC ID(s) | 6585 |
| Cosmic ID(s) | LHCGR |
| KEGG Gene ID(s) | hsa:3973 |
| PharmGKB ID(s) | PA30357 |
| General Description of Luteinizing Hormone / LHCGR. | |
| Recognizes a protein of 78-85kDa, which is identified as Luteinizing hormone / choriogonadotropin receptor. Luteinizing hormone plays a role in spermatogenesis and ovulation by stimulating the testes and ovaries to produce steroids. Choriogonadotropin production in the placenta maintains estrogen and progesterone levels during the first trimester of pregnancy. Ovaries and testes abundantly express luteinizing hormone / choriogonadotropin receptor (LHCGR) as a seven transmembrane, G protein-coupled receptor glycoprotein. LHCGR influences the protective effect of pregnancy and Gonadotropin against breast cancer. The expression of LHCGR on breast carcinoma correlates in part to the degree of tumor differentiation. LHCGR -positive breast tumors occur more frequently in tumors with greater cell differentiation in premenopausal women. | |
Limitations and Warranty
enQuire Bio’s Luteinizing Hormone / LHCGR Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.